Literature DB >> 24708931

Utility of the reverse wire technique in multidetector computed tomography-guided percutaneous transluminal septal myocardial ablation.

Yuichiro Maekawa1, Masahiro Jinzaki2, Atsushi Anzai3, Keisuke Matsumura4, Hikaru Tsuruta3, Takashi Kawakami3, Kentaro Hayashida3, Shinsuke Yuasa3, Mitsushige Murata3, Masahiro Suzuki4, Sachio Kuribayashi2, Keiichi Fukuda3.   

Abstract

Keywords:  Hypertrophic obstructive cardiomyopathy; Multidetector computed tomography; Percutaneous transluminal septal myocardial ablation; Reverse wire technique

Mesh：

Year:  2014        PMID： 24708931     DOI： 10.1016/j.ijcard.2014.03.057

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN： 0167-5273            Impact factor:   4.164


× No keyword cloud information.
  3 in total

1.  Ameliorating the severity of sleep-disordered breathing concomitant with heart failure status after percutaneous transluminal septal myocardial ablation for drug-refractory hypertrophic obstructive cardiomyopathy.

Authors:  Keitaro Akita; Yuichiro Maekawa; Takashi Kohno; Hikaru Tsuruta; Mitsushige Murata; Keiichi Fukuda
Journal:  Heart Vessels       Date:  2017-05-29       Impact factor: 2.037

2.  Significant reduction of left atrial volume concomitant with clinical improvement after percutaneous transluminal septal myocardial ablation for drug-refractory hypertrophic obstructive cardiomyopathy, and its precise detection with multidetector CT.

Authors:  Yuichiro Maekawa; Keitaro Akita; Hikaru Tsuruta; Yoshitake Yamada; Kentaro Hayashida; Shinsuke Yuasa; Mitsushige Murata; Masahiro Jinzaki; Keiichi Fukuda
Journal:  Open Heart       Date:  2016-06-03

3.  Prognostic significance of repeated brain natriuretic peptide measurements after percutaneous transluminal septal myocardial ablation in patients with drug-refractory hypertrophic obstructive cardiomyopathy.

Authors:  Keitaro Akita; Hikaru Tsuruta; Shinsuke Yuasa; Mitsushige Murata; Keiichi Fukuda; Yuichiro Maekawa
Journal:  Open Heart       Date:  2018-05-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.